Citius Pharmaceuticals filings document a Nasdaq-listed biopharmaceutical issuer with common stock registered on The Nasdaq Capital Market and a majority-owned oncology subsidiary. Recent Form 8-K disclosures cover material definitive agreements, registered direct offerings, pre-funded warrants, common warrants, unregistered equity securities and amendments to a promissory note involving Citius Oncology.
The company’s regulatory filings also record LYMPHIR commercial updates, international shipment disclosures, investigator-initiated oncology study announcements, and other material events incorporated through press-release exhibits. Proxy materials document annual meeting matters, including director elections, auditor ratification and shareholder voting results.
Citius Pharmaceuticals reported its first meaningful LYMPHIR sales but remains deeply unprofitable and capital constrained. Net revenue reached $5.6M for the six months ended March 31, 2026, generating gross profit of $4.5M. However, total operating expenses of $45.7M, including large general and administrative costs and amortization of in-process R&D, led to a net loss of $37.5M and a loss per share of $1.34.
Cash and cash equivalents were $4.6M with negative working capital of about $23.3M, and operating activities used $14.3M of cash over six months. The company recognized a $3.8M gain from selling New Jersey net operating losses but also recorded about $20.1M of termination-related charges and a $19.7M contract cancellation fee after its LYMPHIR bulk drug substance manufacturer ended the supply agreement and exited microbial production.
Management’s going concern note states there is substantial doubt about Citius’s ability to continue beyond November 2026 without new funding. Subsequent events include a $5.0M registered direct offering at $0.985 per share, approximately $11.5M of Citius Oncology warrant-inducement proceeds, and a loan facility of up to $25.0M for Citius Oncology bearing at least 12.75% interest. Both Citius Pharma and Citius Oncology also received Nasdaq notices for minimum bid-price deficiencies.
Citius Pharmaceuticals, Inc. entered into a Third Amendment to a promissory note with its majority-owned subsidiary, Citius Oncology, Inc., originally issued on August 16, 2024 in the principal amount of $3,800,111. The amendment ties repayment so that the entire unpaid principal is due 91 days after Citius Oncology’s senior debt is fully repaid and its related loan and security agreement is terminated. It removes prior maturity triggers linked to capital raises, new debt or equity issuances, or royalty-backed monetizations, and bars cash prepayments before the new maturity date. The amendment also adds a voluntary feature allowing the Company, with Citius Oncology’s approval, to convert some or all principal into common stock at a $0.90 per share conversion price.
Citius Pharmaceuticals, Inc., through its majority-owned subsidiary Citius Oncology, Inc., reports the first international shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe via a regional distribution partner. LYMPHIR will be provided to eligible patients through Named Patient Programs under local regulations, expanding access beyond the United States.
The filing also notes, by reference, a previously closed registered direct offering of common stock and a concurrent private placement of pre-funded, common, and placement agent warrants. LYMPHIR is an FDA-approved targeted immune therapy for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy and carries a boxed warning for capillary leak syndrome along with detailed safety and use information.
Citius Pharmaceuticals entered into a registered direct offering and concurrent private placement with institutional investors. The company sold 4,730,457 common shares and pre-funded warrants for 345,686 shares at $0.985 and $0.9849, respectively, plus unregistered warrants to purchase up to 5,076,143 shares at $0.86.
Gross proceeds were approximately $5.0 million, with expected net proceeds of about $4.5 million after fees. Citius plans to use the funds to support the commercialization of LYMPHIR™, advance development of its product candidates, and for general corporate purposes.
Citius Pharmaceuticals is registering 4,730,457 shares of common stock and pre-funded warrants to purchase up to 345,686 shares. The shares are being sold at $0.985 per share and the Pre-funded Warrants at $0.9849 each, with the Pre-funded Warrants exercisable for $0.0001 per share.
The offering includes a concurrent private placement of Common Warrants to purchase up to 5,076,143 shares exercisable at $0.86 (not registered here). Net proceeds to the company are estimated at approximately $4.5 million after placement agent fees. Closing is anticipated on or about April 24, 2026, subject to customary conditions.
Citius Pharmaceuticals, Inc. reported results from its 2026 Annual Meeting of stockholders. Shareholders elected seven directors, including Leonard Mazur and Myron Holubiak, to one-year terms ending at the 2027 annual meeting or until successors are elected and qualified.
Stockholders also ratified Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending September 30, 2026, with 8,593,946 shares voting for, 855,866 against and 673,867 abstaining, and no broker non-votes reported on this item.
Citius Pharmaceuticals, through its majority-owned subsidiary Citius Oncology, reported early commercial and clinical progress for LYMPHIR, a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma. Management estimates the initial LYMPHIR market currently exceeds $400 million and is underserved by existing treatments.
The update highlights growing formulary adoption at leading oncology centers, broadening payer coverage, repeat orders, and adequate commercial supply. Citius Oncology is also expanding clinical development via academic collaborations, including studies in diffuse large B-cell lymphoma and solid tumors in combination with checkpoint inhibitor therapy.
Citius Pharmaceuticals, through its majority-owned subsidiary Citius Oncology, reported positive topline results from an investigator-initiated Phase 1 study of LYMPHIR™ (denileukin diftitox-cxdl) plus pembrolizumab in patients with recurrent or refractory gynecologic cancers.
The study in 25 evaluable patients showed no unexpected safety signals or serious immune-related adverse events at any dose level. Among 21 efficacy-evaluable patients, investigators observed a 24% objective response rate and a 48% clinical benefit rate, defined as complete or partial response or stable disease for at least six months.
The trial aimed to identify a recommended Phase 2 dose, and full safety and efficacy data are planned for presentation at an international cancer conference. LYMPHIR is already FDA‑approved and launched for relapsed or refractory Stage I–III cutaneous T‑cell lymphoma, where management estimates the initial market currently exceeds $400 million.
Citius Pharmaceuticals, through majority-owned subsidiary Citius Oncology, reported positive preliminary Phase 1 data for LYMPHIR when given before commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma. In 14 treated patients, investigators observed an 86% overall response rate, including 57% complete and 29% partial responses, with LYMPHIR described as well tolerated and without dose-limiting toxicities. The study was designed to enhance CAR-T effectiveness by depleting regulatory T-cells, and full results were presented at the 2026 Tandem Meetings. The attached exhibit also reiterates LYMPHIR’s existing FDA approval for cutaneous T-cell lymphoma and includes detailed safety warnings, highlighted by a boxed warning for capillary leak syndrome and other serious risks.